ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,187.70
      0.13%
      US Tech 100
      17,623.20
      0.06%
      Dow Jones
      38,884.26
      0.08%
      Brent Oil
      81.995
      -1.05%
      Bitcoin
      62,290.38
      -0.07%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Werewolf Therapeutics Inc (HOWL)

      7. Werewolf Therapeutics Inc (HOWL) News

      HOWL

      Werewolf Therapeutics (HOWL)

      Werewolf Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:HOWL
      DateTimeSourceHeadlineSymbolCompany
      12:51PMiHub NewswireFeaturedCannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa
      05/03/20247:00AMGlobeNewswire Inc.Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
      04/24/202410:05AMGlobeNewswire Inc.Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
      04/23/20248:00AMGlobeNewswire Inc.Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
      04/05/20244:30PMGlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
      04/04/20244:30PMGlobeNewswire Inc.Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
      03/07/20247:22AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOWLWerewolf Therapeutics Inc
      03/07/20247:15AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HOWLWerewolf Therapeutics Inc
      03/07/20247:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
      03/07/20247:00AMGlobeNewswire Inc.Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
      03/06/20248:00AMGlobeNewswire Inc.Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
      03/05/20244:30PMGlobeNewswire Inc.Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024NASDAQ:HOWLWerewolf Therapeutics Inc
      02/09/20244:39PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
      02/09/20244:35PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOWLWerewolf Therapeutics Inc
      01/08/20248:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
      01/04/20247:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
      01/04/20247:13PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
      01/04/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
      01/04/20244:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
      01/04/20244:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
      01/04/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
      01/04/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
      01/04/20244:05PMGlobeNewswire Inc.Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of DirectorsNASDAQ:HOWLWerewolf Therapeutics Inc
      11/22/20237:00AMGlobeNewswire Inc.Werewolf Therapeutics to Present at the Evercore ISI HealthCONx ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
      11/14/20234:34PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
      11/14/20234:25PMGlobeNewswire Inc.Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
      11/03/20237:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
      11/03/20237:00AMGlobeNewswire Inc.Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
      10/31/20239:00AMGlobeNewswire Inc.Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
      09/27/20239:00AMGlobeNewswire Inc.Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:HOWL